Contineum Therapeutics, Inc. Class A Common Stock
CTNM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$42,258 | $22,720 | -$24,253 | -$29,001 |
| Dep. & Amort. | $258 | $195 | $329 | $325 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $6,804 | $2,219 | $1,927 | $1,749 |
| Change in WC | $5,334 | -$1,024 | -$1,267 | $108 |
| Other Non-Cash | -$2,983 | -$4,761 | $3,143 | $553 |
| Operating Cash Flow | -$32,845 | $19,349 | -$20,121 | -$26,266 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$514 | -$414 | -$118 | -$168 |
| Net Acquisitions | $20 | $0 | $0 | $0 |
| Inv. Purchases | -$226,407 | -$141,866 | -$64,699 | -$66,776 |
| Inv. Sales/Matur. | $157,162 | $76,712 | $87,116 | $1,976 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$69,739 | -$65,568 | $22,299 | -$64,968 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | -$3,750 | -$1,250 | $0 |
| Stock Issued | $108,211 | $0 | $0 | $0 |
| Stock Repurch. | $0 | -$28 | -$4 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $790 | $59,954 | $15 | $79,839 |
| Financing Cash Flow | $109,001 | $56,176 | -$1,239 | $79,839 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $6,417 | $9,957 | $939 | -$11,395 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $15,526 | $5,569 | $4,630 | $16,025 |
| End Cash | $21,943 | $15,526 | $5,569 | $4,630 |
| Free Cash Flow | -$33,359 | $18,935 | -$20,239 | -$26,434 |